NGF serum levels variations in major depressed patients receiving duloxetine

Psychoneuroendocrinology

Volumn 38, Issue 9, 2013, Pages 1824-1828

  Martino, Matteo ^a   Rocchi, Giulio ^a   Escelsior, Andrea ^a   Contini, Paola ^a   Colicchio, Salvatore ^b   de Berardis, Domenico ^c   Amore, Mario ^a   Fornaro, Pantaleo ^a   Fornaro, Michele ^a,d  

^a UNIVERSITY OF GENOA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Depression; Duloxetine; Neuro endocrine immune system; NGF

Indexed keywords

DULOXETINE; NERVE GROWTH FACTOR; NEUROTROPHIN;

ADAPTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; NEUROENDOCRINE IMMUNE SYSTEM; NEUROENDOCRINE SYSTEM; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEROTONINERGIC TRANSMISSION;

DEPRESSION; DULOXETINE; NEURO-ENDOCRINE-IMMUNE SYSTEM; NGF;

ADAPTATION, PSYCHOLOGICAL; ADULT; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NEURONAL PLASTICITY; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL; SYMPATHOMIMETICS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883653883     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.02.009     Document Type: Article

References (15)

1. Aisa B., Gil-Bea F.J., Marcos B., Tordera R., Lasheras B., Del Rio J., Ramirez M.J. Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: involvement of the HPA axis. Psychoneuroendocrinology 2009, 34:1495-1505.
2. Alleva E., Petruzzi S., Cirulli F., Aloe L. NGF regulatory role in stress and coping of rodents and humans. Pharmacol. Biochem. Behav. 1996, 54:65-72.
3. Aloe L., Alleva E., Fiore M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol. Biochem. Behav. 2002, 73:159-166.
4. Cirulli F., Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front. Neuroendocrinol. 2009, 30:379-395.
5. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 2010, 113:649-660.
6. Faure J., Uys J.D., Marais L., Stein D.J., Daniels W.M. Early maternal separation followed by later stressors leads to dysregulation of the HPA-axis and increases in hippocampal NGF and NT-3 levels in a rat model. Metab. Brain Dis. 2006, 21:181-188.
7. Hadjiconstantinou M., McGuire L., Duchemin A.M., Laskowski B., Kiecolt-Glaser J., Glaser R. Changes in plasma nerve growth factor levels in older adults associated with chronic stress. J. Neuroimmunol. 2001, 116:102-106.
8. Hassanzadeh P., Rahimpour S. The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl) 2011, 215:129-141.
9. Hellweg R., Thomas H., Arnswald A., von Richthofen S., Kay S., Fink H., Morgenstern R., Hortnagl H. Serotonergic lesion of median raphe nucleus alters nerve growth factor content and vulnerability of cholinergic septohippocampal neurons in rat. Brain Res. 2001, 907:100-108.
10. Hellweg R., Ziegenhorn A., Heuser I., Deuschle M. Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment. Pharmacopsychiatry 2008, 41:66-71.
11. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49:391-404.
12. Rattray M. Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease. Biol. Psychiatry 2001, 49:185-193.
13. Schulte-Herbruggen O., Hellweg R., Chourbaji S., Ridder S., Brandwein C., Gass P., Hortnagl H. Differential regulation of neurotrophins and serotonergic function in mice with genetically reduced glucocorticoid receptor expression. Exp. Neurol. 2007, 204:307-316.
14. Schulte-Herbruggen O., Fuchs E., Abumaria N., Ziegler A., Danker-Hopfe H., Hiemke C., Hellweg R. Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. J. Neurosci. Res. 2009, 87:2551-2560.
15. Xiong P., Zeng Y., Wan J., Xiaohan D.H., Tan D., Lu J., Xu F., Li H.Y., Zhu Z., Ma M. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011, 189:72-76.